文献速递糖尿病肥胖与代谢综合征

体型对临床前1型糖尿病发生与进展的影响

Impact of Body Size on Preclinical Type 1 Diabetes Development and Progression.
PubMed 文献 · Diabetes Care · 2026-01-01

本文综述TEDDY、TrialNet等队列证据,指出BMI与肥胖可影响胰岛自身免疫启动、临床前阶段进展及3期1型糖尿病发生。该关联在低龄儿童、西班牙裔及特定HLA基因型者中更明显,涉及胰岛素抵抗、β细胞应激、脂肪组织炎症等机制。

要点

  • 肥胖是可干预的1型糖尿病环境危险因素。
  • 体型相关风险在低龄儿童、西班牙裔及特定HLA型中更高。
  • 机制涉及胰岛素抵抗、β细胞应激与脂肪炎症等。

核心结论

  • BMI与肥胖同胰岛自身免疫启动、临床前阶段进展及3期1型糖尿病发生相关。
  • 该关联并不均一,部分人群对肥胖相关风险更易感。
  • 肥胖相关免疫与代谢通路可能成为精准预防的靶点。

研究设计与样本

  • 综述整合TEDDY、Type 1 Diabetes TrialNet及其他纵向队列证据。
  • 讨论遗传易感与环境暴露交互导致自身免疫性β细胞破坏的框架。

主要发现

  • BMI与脂肪量与胰岛自身免疫启动、临床前阶段进展及3期1型糖尿病相关。
  • 肥胖相关风险在低龄儿童、西班牙裔人群及特定HLA基因型者中更高。
  • 涉及胰岛素抵抗、β细胞应激、脂肪组织炎症、脂肪因子信号改变及肠道菌群变化。

临床怎么用

  • 对有肥胖的临床前1型糖尿病个体,可评估BMI作为可干预风险因素。
  • 关注低龄儿童、西班牙裔及特定HLA基因型者的肥胖相关风险。
  • 未来研究应评估降低BMI或靶向肥胖相关通路能否改变临床前轨迹。

局限性

  • 连接BMI升高与自身免疫性β细胞破坏的生物学通路尚未完全阐明。
  • 相关机制与生物标志物仍需进一步研究以推进精准预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes arises from the interplay of genetic susceptibility and environmental exposures, leading to autoimmune β-cell destruction. Although disease-modifying therapies (DMTs) can delay progression to clinical (stage 3) type 1 diabetes, treatment responses remain inconsistent and transient. The marked heterogeneity of type 1 diabetes, shaped by age, sex, race or ethnicity, and genetic background, underscores the need to elucidate distinct mechanistic pathways. Among environmental contributors, obesity stands out as a compelling modifiable target. Data from The Environmental Determinants of Diabetes in the Young (TEDDY), Type 1 Diabetes TrialNet, and other longitudinal cohorts link BMI and adiposity to the onset of islet autoimmunity, progression through preclinical stages, and development of stage 3 type 1 diabetes. These associations are not uniform; heightened susceptibility to adiposity-related risk is seen among younger children, Hispanic populations, and individuals with specific HLA genotypes. Despite robust epidemiologic evidence, the biological pathways connecting elevated BMI to autoimmune β-cell destruction remain incompletely defined. Emerging data implicate a network of immunologic and metabolic disturbances, including insulin resistance, β-cell stress, chronic adipose tissue inflammation, altered adipokine signaling, and gut microbiome changes, that collectively heighten β-cell vulnerability, amplify autoreactive immune responses, and drive metabolic decompensation toward clinical disease. Elucidating these mechanisms and identifying related biomarkers are critical to advancing precision prevention. In future studies, investigators should evaluate whether modifying elevated BMI or targeting obesity-associated immunologic and metabolic pathways can alter the preclinical trajectory of type 1 diabetes. Such mechanistic understanding may help curb type 1 diabetes incidence and improve outcomes for populations most vulnerable to obesity-related risk.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Gupta RM, Ismail HM, Siller AF, et al. Impact of Body Size on Preclinical Type 1 Diabetes Development and Progression. Diabetes Care. 2026. PMID: 41915459. doi:10.2337/dci25-0134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。